VRNA News and Press, Verona Pharma plc From 05/25/24

2024-05-25 00:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-23 13:23:32 ET Summary Verona Pharma plc stock has lost most of its gains from a strong rally late last year. However, the company has a pivotal FDA decision coming up next month around its primary candidate Ensifentrine. Verona has secured necessary funding to support...

2024-05-09 13:54:49 ET More on Verona Pharma Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript Verona Pharma plc (VRNA) Q4 2023 Earnings Call Transcript Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation Verona Pharma GAAP EPS of -$0.04 ...

2024-05-09 12:31:02 ET Verona Pharma plc (VRNA) Q1 2024 Results Conference Call May 09, 2024 9:00 AM ET Company Participants David Zaccardelli - President, CEO & Executive Director Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Offi...

2024-05-09 07:23:47 ET More on Verona Pharma Verona Pharma: A Few Points From The Bull And Bear Case Seeking Alpha’s Quant Rating on Verona Pharma Historical earnings data for Verona Pharma Read the full article on Seeking Alpha For further det...

PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 09, 2024...

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”),...

2024-05-08 11:18:10 ET More on Verona Pharma Verona Pharma: A Few Points From The Bull And Bear Case Seeking Alpha’s Quant Rating on Verona Pharma Historical earnings data for Verona Pharma Read the full article on Seeking Alpha For further det...

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma...

LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investme...